Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with alopecia perceive their hair loss as more severe than dermatologists do, and their own ratings of hair loss severity better reflect their quality of life impacts.

In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.

This article reviews recent updates on alopecia areata, focusing on its causes, clinical presentation, and treatment options, and provides treatment plans by patient age and disease extent, but reports no new clinical results.

The 308-nm excimer laser helps hair regrowth in some alopecia areata cases but not all.

This study found that 67% of children treated with diphencyprone for alopecia areata or alopecia totalis regrew scalp hair, with 33% achieving complete regrowth.

This study observed that most pediatric patients with alopecia areata experienced some hair regrowth after treatment with topical JAK inhibitors, and the formulations were generally well-tolerated with mild lab abnormalities in some cases.

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

This study found that using a low-level laser comb led to hair regrowth in a mouse model of alopecia areata, while sham-treated mice showed no hair regrowth.

This study found that 1% topical minoxidil induced significant hair regrowth in patients with alopecia areata, though it was less effective for those with extensive hair loss such as alopecia totalis and universalis.

This study found that while some patients with severe alopecia areata responded to high-dose prednisolone, the response was inconsistent and the therapy's risks prevent recommending it for general use.

This article proposes that alopecia areata may be caused by immune attacks on hair follicles after an immune privilege collapse, suggesting new therapeutic approaches targeting this immune response pattern.

This study found that the 308-nm Excimer laser was effective and safe for treating patchy alopecia areata in children, with hair regrowth observed in 60% of treated scalp patches.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

This study found that 1% minoxidil topical solution led to terminal hair regrowth in some patients with alopecia areata, though it was only cosmetically acceptable in less than half of those cases.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

CD44 variant changes start alopecia areata, but don't maintain it.

In this study, researchers identified yellow dots as the most common dermoscopic feature of alopecia areata, followed by black dots, broken hairs, short vellus hair, and tapering hairs.

This study reported that the prevalence of alopecia areata in the US slightly increased from 0.199% to 0.222% between 2016 and 2019, with higher rates observed in women and adults.

This study developed an animal model that recreates alopecia areata by injecting healthy human skin grafts in immunocompromised mice with peripheral blood mononuclear cells enriched for NKG2D+ and CD56+ cells.

In this case report, a patient experienced a recurrence of alopecia areata while undergoing etanercept treatment, suggesting the drug may not effectively prevent this condition's return.

This study found that both intralesional triamcinolone acetonide and triamcinolone hexacetonide promote continuous hair growth in alopecia areata, with effects lasting at least 9 months after a single injection.

This review identifies shared interferon gamma-driven immune pathways in vitiligo and alopecia areata, revealing potential targets for new treatments, but reports no clinical results.

This review analyzed randomized controlled trials on alopecia areata treatment and found that while several treatments showed effectiveness, most studies had limitations affecting their interpretability.

This study found that anti-TNF therapy-induced alopecia exhibits distinct clinical and histopathological features and can mimic psoriatic alopecia and alopecia areata, with some patients improving with topical treatment.

This review discusses current and emerging drug therapies for treating androgenetic alopecia and alopecia areata, and reports no clinical results; it highlights a need for improved and novel treatments.

This review discusses various treatments for alopecia areata, highlighting their limitations and individualized approach, and reports no new clinical results.

This review discusses the similar immune pathways and genetic risk factors of vitiligo and alopecia areata but reports no new clinical findings, emphasizing the potential for shared treatment research.

This review discusses evidence for alopecia areata treatments, highlighting their ability to stimulate hair growth but noting limited data on long-term efficacy and impact on quality of life.

This review discusses the use of animal models to study alopecia areata and reports no new experimental results, emphasizing the potential for these models to explore the disease's genetics and treatment.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.